Brief: Dynavax Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Full Year 2024 Financial Guidance
Feb 22 (Reuters) - Dynavax Technologies Corp DVAX.O :
* DYNAVAX REPORTS FOURTH QUARTER AND FULL YEAR 2023
FINANCIAL
RESULTS AND PROVIDES FULL YEAR 2024 FINANCIAL GUIDANCE
* DYNAVAX TECHNOLOGIES CORP: QTRLY EARNINGS PER SHARE $0.00
* DYNAVAX TECHNOLOGIES CORP: CASH POSITION INCREASED TO $742
MILLION AT YEAR END AND EXPECT TO BE CASH FLOW POSITIVE FOR FULL
YEAR 2024
* DYNAVAX TECHNOLOGIES CORP: 2024 HEPLISAV-B NET PRODUCT
REVENUE
EXPECTED TO BE $265 - $280 MILLION
Further company coverage: DVAX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dynavax Technologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
OneSpaWorld jumps as co poised to join S&P SmallCap index
Sanofi targets high single digit sales growth in 2026, plans share buyback (updated)
Focus: Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality